Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological, Cardiovascular, and Smooth Muscle Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNMA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNMA1 Recombinant Protein (Intracellular Gating Domain Fragment / Extracellular Domain). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW. | View KCNMA1 Products |
| Gene Delivery | KCNMA1 Promise-ORF / Lentivirus Premade Particles (>10^8 TU/mL). Full-length ORF for stable cell line construction. HEK293 expressed, native glycosylation and membrane topology preserved. | View KCNMA1 Products |
| Benchmark Ab | Anti-KCNMA1 (Recombinant Positive Control). Sequence-verified benchmark antibody for expression validation and assay optimization. | View KCNMA1 Products |
| Validator | KCNMA1 siRNA Set. For knockdown verification and specificity control in functional assays. | View KCNMA1 Products |
| Related Target: KCNMB1 | KCNMB1 (BK Beta-1 Regulatory Subunit). Co-assembles with KCNMA1 to define calcium sensitivity and tissue-specific pharmacology in smooth muscle. | View KCNMB1 Products |
| Related Target: KCNMB2 | KCNMB2 (Beta-2 Subunit). Neuronal-specific auxiliary subunit; alters toxin binding affinity and inactivation. | View KCNMB2 Products |
| Related Target: KCNMB4 | KCNMB4 (BK Beta-4 Regulatory Subunit). Neuronal-enriched beta subunit that modulates gating kinetics; critical for CNS-targeted modulator selectivity. | View KCNMB4 Products |
| Related Target: CACNA1C | CACNA1C (Cav1.2). L-type voltage-gated calcium channel functionally coupled with KCNMA1 in vascular smooth muscle. | View CACNA1C Products |
| Related Target: KCNN4 | KCNN4 (IK1). Intermediate-conductance calcium-activated potassium channel for selectivity counter-screening. | View KCNN4 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native conformational integrity for ion channel functional assays | Lentivirus-mediated stable expression in HEK293 preserves native glycosylation and membrane topology; verified by surface staining. |
| Beta subunit-dependent pharmacology and tissue selectivity | Co-expression systems: KCNMA1 + KCNMB1/KCNMB2/KCNMB4 lentiviral particles available for heteromeric channel assays. |
| Cross-species toxicity and efficacy evaluation (cyno / mouse / rat) | Human / Mouse / Rat / Cyno KCNMA1 ortholog ORF clones with sequence-verified identity for species-specific stable lines. |
| Off-target activity across the ion channel superfamily | Strict sequence verification, KCNN4 / KCNQ panel, and siRNA controls included to confirm on-target MoA and rule out assay artifacts. |
| Knockdown validation | Validated siRNA included for target specificity confirmation in functional assays. |
Live KCNMA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNMA1-targeted therapeutics is evolving from non-selective small-molecule openers toward precision modulators that exploit beta-subunit composition, state-dependent binding, and gene therapy for rare mutations. First-generation compounds (e.g., BMS-204352) faced setbacks due to ubiquitous tissue expression leading to systemic hypotension. The next wave targets:
- Rare neurological disorders driven by gain-of-function KCNMA1 mutations (e.g., PNKD3, epilepsy) via AAV/ASO gene therapy and mutation-specific small molecules.
- Tissue-selective small molecules co-targeting specific KCNMB paralogs (e.g., KCNMB1 in smooth muscle, KCNMB4 in CNS) to avoid off-tissue side effects.
- Engineered peptide toxins (e.g., Iberiotoxin derivatives) for pain and neuroprotection.
- Targeted degradation (PROTACs) for oncology indications where BK channel overexpression is observed.
Key therapeutic areas undergoing paradigm shifts: neurological (stroke, epilepsy, movement disorders), smooth muscle (overactive bladder, hypertension), and rare genetic channelopathies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators/Openers | Neurocrine, BMS (legacy), Emerging Biotechs | Epilepsy, Dyskinesia, Overactive Bladder, Stroke, Hypertension | Automated patch-clamp & thallium flux assays using full-length lentivirus stable lines with confirmed surface expression. |
| Gene Therapy (AAV/ASO) | Spark Therapeutics, uniQure, academic consortia | KCNMA1-Related Encephalopathy, Movement Disorders (PNKD3), Epilepsy | Expression validation & functional current confirmation; disease-mutation constructs (e.g., D434G, A138T, G354S) for rescue assays. |
| Peptide Toxins / Biologics | Academic labs & biotech spin-offs | Pain, Neuroprotection, Smooth Muscle Disorders | Binding assays using extracellular domain protein; heterodimer validation with KCNMB1/2/4 lentivirus. |
| Beta Subunit Selective Modulators | Stealth-mode biotechs | Smooth Muscle Specificity (OAB, Hypertension) | Heterodimer assay: KCNMA1+KCNMB1 co-expression required for beta-specific pharmacology. |
| Targeted Degraders (PROTACs) | Emerging Biotechs | Oncology (Breast, Prostate) | Degradation assays requiring specific benchmark antibody and siRNA controls. |
Key Mutation Insights
KCNMA1 is associated with several clinically relevant mutations:
- rs1554829003 (LIWAS): Loss of voltage-gated potassium channel activity.
- PNKD3 variant: Synergistic effect with ethanol in triggering symptoms.
- CADEDS variant: Associated with a distinct syndrome.
These mutations highlight the need for mutation-specific functional assays (e.g., electrophysiology on mutant channels) for rare disease drug development.
Functional Domains
KCNMA1 contains two RCK N-terminal domains (RCK N-terminal 1 and 2) that are critical for calcium sensitivity and channel gating. Targeting these domains with allosteric modulators offers a path to state-dependent pharmacology.